Two melanoma treatments approved for PBS listing
24 December 2019
In a boost for melanoma patients across Australia, the Federal Government’s PBAC has recommended subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients. Two melanoma treatments are recommended by the PBAC for PBS listing - nivolumab for resected Stage III/IV (high risk) metastatic melanoma, and the combination ipilimumab and nivolumab as first-line therapy for Stage IV (advanced) melanoma.
Co-Medical Directors of Melanoma Institute Australia, Professor Georgina Long and Professor Richard Scolyer, said providing subsidised access to these treatments was wonderful news for melanoma patients and their families around Australia, as until now, they could only access these treatments through clinical trials or on compassionate grounds, or face costs of tens of thousands of dollars.
‘Our clinical trials have proven nivolumab is effective in preventing melanoma recurrence and its spread to other organs including the brain, lungs and liver in the majority of high risk resected Stage III patients,’ said Professor Georgina Long. ‘Our trials have also proven the effectiveness of the combination immunotherapy as front line treatment for Stage IV melanoma patients where their disease has already spread to other organs, including the brain.’
‘Providing certainty of access to these treatments via the PBS will be life-changing and life-saving, and we applaud the Federal Government for this decision,’ added Professor Richard Scolyer.
Shown in photo: Melanoma Institute Australia's Co-Medical Directors - Professor Georgina Long and Professor Richard Scolyer
MIA joins Sydney Health Partners
Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.
Olympians join forces for melanoma warning
Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
Honouring the exceptional impact of his work on communities around the world.
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
Awarded for their life-saving discoveries transforming melanoma patient care.
Aussies urged to mark start of summer by checking their skin
National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
AMC2021 conference wrap-up
Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.
Journalist and news reader Peter Overton our new National Ambassador
Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.
New research into importance of skin surveillance to save lives from melanoma
New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.
Game On Mole - saving lives this summer
With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever.
Melanoma March physical events in 2022
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Community Fundraising Wrap Up July-Sept 2021
Read more about the wonderful MIA community fundraising initiatives held recently.
Australian researchers spearhead paradigm shift in melanoma treatment
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Melanoma Bike Bash 2021: What a ride!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
MIA researchers awarded $7.2m in NHMRC grants for health research
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
Amie St Clair Ball in Wagga postponed for a third time
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Honouring Ben's life by supporting the next generation of melanoma researchers
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.